Se afișează postările cu eticheta Younger. Afișați toate postările
Se afișează postările cu eticheta Younger. Afișați toate postările

duminică, 5 august 2012

Alzheimer's Found To Be More Aggressive Among Younger Elderly But Slows In Advanced Age

dj nunta | dj botez | Birou notarial | Baloane | Aranjamente Baloane | aranjamente florale | flori nunta | flori botez | Pret Aparat Dentar | Aparat Dentar Invizibil | instrumentar | biomateriale | stomatologie
Main Category: Alzheimer's / Dementia
Also Included In: Seniors / Aging
Article Date: 05 Aug 2012 - 0:00 PDT Current ratings for:
Alzheimer's Found To Be More Aggressive Among Younger Elderly But Slows In Advanced Age
not yet ratednot yet rated
The greatest risk factor for Alzheimer's disease (AD) is advancing age. By age 85, the likelihood of developing the dreaded neurological disorder is roughly 50 percent. But researchers at the University of California, San Diego School of Medicine say AD hits hardest among the "younger elderly" - people in their 60s and 70s - who show faster rates of brain tissue loss and cognitive decline than AD patients 80 years and older.

The findings, reported online in the journal PLOS One, have profound implications for both diagnosing AD - which currently afflicts an estimated 5.6 million Americans, a number projected to triple by 2050 - and efforts to find new treatments. There is no cure for AD and existing therapies do not slow or stop disease progression.

"One of the key features for the clinical determination of AD is its relentless progressive course," said Dominic Holland, PhD, a researcher at the Department of Neurosciences at UC San Diego and the study's first author. "Patients typically show marked deterioration year after year. If older patients are not showing the same deterioration from one year to the next, doctors may be hesitant to diagnose AD, and thus these patients may not receive appropriate care, which can be very important for their quality of life."

Holland and colleagues used imaging and biomarker data from participants in the Alzheimer's Disease Neuroimaging Initiative, a multi-institution effort coordinated at UC San Diego. They examined 723 people, ages 65 to 90 years, who were categorized as either cognitively normal, with mild cognitive impairment (an intermediate stage between normal, age-related cognitive decline and dementia) or suffering from full-blown AD.

"We found that younger elderly show higher rates of cognitive decline and faster rates of tissue loss in brain regions that are vulnerable during the early stages of AD," said Holland. "Additionally cerebrospinal fluid biomarker levels indicate a greater disease burden in younger than in older individuals."

Holland said it's not clear why AD is more aggressive among younger elderly.

"It may be that patients who show onset of dementia at an older age, and are declining slowly, have been declining at that rate for a long time," said co-author Linda McEvoy, PhD, associate professor of radiology. "But because of cognitive reserve or other still-unknown factors that provide 'resistance' against brain damage, clinical symptoms do not manifest till later age."

Another possibility, according to Holland, is that older patients may be suffering from mixed dementia - a combination of AD pathology and other neurological conditions. These patients might withstand the effects of AD until other adverse factors, such as brain lesions caused by cerebrovascular disease, take hold. At the moment, AD can only be diagnosed definitively by an autopsy. "So we do not yet know the underlying neuropathology of participants in this study," Holland said.

Clinical trials to find new treatments for AD may be impacted by the differing rates, researchers said. "Our results show that if clinical trials of candidate therapies predominately enroll older elderly, who show slower rates of change over time, the ability of a therapy to successfully slow disease progression may not be recognized, leading to failure of the clinical trial," said Holland. "Thus, it's critical to take into account age as a factor when enrolling subjects for AD clinical trials."

The obvious downside of the findings is that younger patients with AD lose more of their productive years to the disease, Holland noted. "The good news in all of this is that our results indicate those who survive into the later years before showing symptoms of AD will experience a less aggressive form of the disease."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our alzheimer's / dementia section for the latest news on this subject. Co-authors are Rahul S. Desikan, Department of Radiology, UCSD and Anders M. Dale, Departments of Neurosciences and Radiology, UCSD.
Funding for this research came, in part, from the National Institutes of Health (grants R01AG031224, R01AG22381, U54NS056883, P50NS22343 and P50MH08755); the National Institute on Aging (grant K01AG029218) and the National Institute of Biomedical Imaging and Bioengineering (grant T32EB005970).
University of California - San Diego Please use one of the following formats to cite this article in your essay, paper or report:

MLA

n.p. "Alzheimer's Found To Be More Aggressive Among Younger Elderly But Slows In Advanced Age." Medical News Today. MediLexicon, Intl., 5 Aug. 2012. Web.
5 Aug. 2012. APA

Please note: If no author information is provided, the source is cited instead.


'Alzheimer's Found To Be More Aggressive Among Younger Elderly But Slows In Advanced Age'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



dj nunta | dj botez | Birou notarial | Baloane | Aranjamente Baloane | aranjamente florale | flori nunta | flori botez | Pret Aparat Dentar | Aparat Dentar Invizibil | instrumentar | biomateriale | stomatologie

duminică, 11 decembrie 2011

Breast Cancer Survival In Younger Breast Cancer Patients Improves With Bone Drug

Editor's Choice
Main Category: Breast Cancer
Also Included In: Bones / Orthopedics;  Cancer / Oncology
Article Date: 10 Dec 2011 - 18:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
5 starsnot yet rated
Zometa (zoledronic acid), used to protect bone health in pre-menopausal ER-Positive breast cancer patients, has been found to improve survival considerably. In fact, it had as beneficial an effect on survival as chemotherapy, researchers from the University of Vienna, Austria, reported in the 2011 CTRC-AACR San Antonio Breast Cancer Symposium this week.

The scientists reported that not only did zoledronic acid reduce death risk by 36%, but also that the risk of breast cancer recurrence dropped 28%. Patients were administered zoledronic acid along with adjuvant endocrine treatment, including ovarian function suppression.

The researchers presented data after 48, 62 and 84 months of follow-up. At 7 years there were "drastically" fewer breast cancer recurrences and better survival rates - and no reports of toxic side effects.

Professor of Surgery, at the University of Vienna's Medical School, Michael Gnant, M.D.,said:

"We have confirmed what this trial showed initially, which was both exciting and surprising. The continued success of this treatment means we can intervene early and still observe persistence of the benefit of treatment."

Dr. Gnant is also President of the ABCSG (Austrian Breast- and Colorectal Cancer Study Group).

The trial involved 1,803 women, all of them premenopausal with early-stage ER (estrogen receptor)-positive breast cancer. They were randomly selected to one of the four arms of the study. They were administered the following drugs or combinations for 36 months: AnastrazoleTamoxifenZoledronic acid plus anastrazoleZoledronic acid plus tamoxifenIn 2008, an initial report showed that there had been a significant improvement in disease-free survival in the females receiving zoledronic acid.

According to the latest data at 84 months post-treatment, the patients on zoledronic acid had a 36% lower risk of death and a 29% smaller chance of the cancer coming back (recurrence). There were no reports of any patient developing renal failure or osteonecrosis (bone death) of the jaw. Gnant explained that this means the treatment is not only effective after seven years, but also safe.

The participants aged over 40 with presumed complete ovarian blockade were 34% less likely to experience cancer recurrence, and also had a 44% lower risk of death. For patients under 40 there appeared to be no significant survival benefits.

The team concluded that zoledronic acid, added to adjuvant endocrine therapy (including ovarian function suppression), should be a considered treatment option for females with ER-positive early breast cancer who have not yet reached the menopause.

Zoledronic acid, also known as zoledronate, molecular formula C5H10N2O7P2, is a bisphosphonate, which is made and marketed by the Swiss company Novartis under the brand names Aclasta, Reclast, Zomera and Zometa. Zometa is prescribed to prevent bone fractures in patients with several types of cancers. Zoledronic acid is also used for osteoporosis treatment, and hypercalcemia of malignancy.

Written by Christian Nordqvist


Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today Visit our breast cancer section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Christian Nordqvist. "Breast Cancer Survival In Younger Breast Cancer Patients Improves With Bone Drug." Medical News Today. MediLexicon, Intl., 10 Dec. 2011. Web.
11 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

vineri, 9 decembrie 2011

Bilateral Oophorectomy Associated With Higher Prevalence Of Low Bone Mineral Density And Arthritis In Younger Women

Main Category: Arthritis / Rheumatology
Also Included In: Bones / Orthopedics
Article Date: 09 Dec 2011 - 2:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
Women who underwent surgery to remove their ovaries before the age of 45 years were more likely to have arthritis and low bone mineral density compared with women with intact ovaries, researchers found.

Anne Marie McCarthy, Sc.M., a doctoral candidate in epidemiology at Johns Hopkins Bloomberg School of Public Health, presented the results at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

"Our study suggests that some women with oophorectomy, particularly at a young age, can experience clinically relevant decreases in bone mineral density (BMD). Clinicians need to be aware of this so they can intervene early if required," McCarthy said.

She and senior investigator Kala Visvanathan, M.D., MHS, associate professor at Johns Hopkins Sidney Kimmel Cancer Center and Bloomberg School of Public Health, examined associations of oophorectomy with arthritis and BMD in the Third National Health and Nutrition Examination Survey (NHANES III), a nationally representative survey conducted from 1988 to 1994.

The BMD analysis included 3,660 women, and the arthritis analysis included 4,039 women. Women aged 40 years and older who had no cancer history and reported a bilateral oophorectomy or intact ovaries were included for analysis.

Researchers used dual-energy X-ray to measure BMD in the femoral neck.

Women who had both ovaries removed before 45 years of age and who never used HRT had a lower BMD on average than women with intact ovaries (0.691 g/cm2 vs. 0.729 g/cm2, respectively). They were also twice as likely to have very low bone mineral density compared to women with intact ovaries.

Participants were also asked if they had been diagnosed with arthritis. Researchers found that 45.4 percent of women who had oophorectomy reported arthritis compared with 32.1 percent of women with intact ovaries. They found a higher prevalence of arthritis 47.7 percent among women who had undergone oophorectomy before 45 years of age.

"[The study] highlights the need for more research in this area to identify those women at risk and to determine appropriate screening and preventive strategies for these young women," McCarthy said.

She added that NHANES III is a cross-sectional study, so "therefore, we cannot make statements on whether oophorectomy actually causes osteoporosis or arthritis at this time."

Article adapted by Medical News Today from original press release. Source: American Association for Cancer Research
Visit our arthritis / rheumatology section for the latest news on this subject. American Association for Cancer Research Please use one of the following formats to cite this article in your essay, paper or report:

MLA

American Association for Cancer Research. "Bilateral Oophorectomy Associated With Higher Prevalence Of Low Bone Mineral Density And Arthritis In Younger Women." Medical News Today. MediLexicon, Intl., 9 Dec. 2011. Web.
9 Dec. 2011. APA
American Association for Cancer Research. (2011, December 9). "Bilateral Oophorectomy Associated With Higher Prevalence Of Low Bone Mineral Density And Arthritis In Younger Women." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/238916.php.

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here